The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Immunotherapy for advanced renal cell cancer
Abstract
BACKGROUND: The course of advanced renal cell carcinoma is extremely variable, ranging from spontaneous remission to disease progression refractory to chemotherapy. Immunotherapy has held promise of improved outcomes based on uncontrolled studies and randomized controlled trials generally limited by small size and low power. OBJECTIVES: To evaluate immunotherapy for advanced renal cell carcinoma by comparing: (1) high dose interleukin-2 to other options and (2) interferon-alfa to other options. The primary outcome of interest was overall survival at one year, with remission as the main secondary outcome of interest. SEARCH STRATEGY: A systematic search of the CENTRAL, MEDLINE, and EMBASE databases was conducted for the period 1966 through end of December 2003. Handsearches were made of the proceedings of the periodic meetings of the American Urologic Association, the American Society of Clinical Oncology, ECCO - the European Cancer Conference, and the European Society of Medical Oncology for the period 1995 to June 2004. SELECTION CRITERIA: Randomized controlled trials that selected (or stratified) patients with advanced renal cell carcinoma, utilized an immunotherapeutic agent in at least one study arm, and reported remission or survival by allocation. Fifty-three identified studies involving 6117 patients were eligible and all but one reported remission; 32 of these studies reported the one-year survival outcome. DATA COLLECTION AND ANALYSIS: Two reviewers independently abstracted each article by following a prospectively designed protocol. Dichotomous outcomes for treatment remission (partial plus complete) and for deaths at one year were used for the main comparisons. Survival hazard ratios were also used for studies of interferon-alfa versus controls, and for two randomized studies of the value of initial nephrectomy prior to interferon-alfa in fit patients with metastases detected at the time of diagnosis. MAIN RESULTS: Combined data for a variety of immunotherapies gave an overall chance of partial or complete remission of only 12.9% (99 study arms), compared to 2.5% in 10 non-immunotherapy control arms, and 4.3% in two placebo arms. Twenty-eight percent of these remissions were designated as complete (data from 45 studies). Median survival averaged 13.3 months (range by arm, 6 to 27+ months). The difference in remission rate between arms was poorly correlated with the difference in median survival so that remission rate is not a good surrogate or intermediate outcome for survival for advanced renal cancer. We were unable to identify any published randomized study of high-dose interleukin-2 versus a non-immunotherapy control, or of high-dose interleukin-2 versus interferon-alfa reporting survival. It has been established that reduced dose interleukin-2 given by intravenous bolus or by subcutaneous injection provides equivalent survival to high dose interleukin-2 with less toxicity. Results from four studies (644 patients) indicate that interferon-alfa is superior to controls (OR for death at one year = 0.56, 95% confidence interval 0.40 to 0.77). Using the method of Parmar 1998, the pooled overall hazard ratio for death was 0.74 (95% confidence interval 0.63 to 0.88). The weighted average median improvement in survival was 3.8 months. T he optimal dose and duration of interferon-alfa remains to be elucidated. The addition of a variety of enhancers, including lower dose intravenous or subcutaneous interleukin-2, has failed to improve survival compared to interferon-alfa alone. Two recent randomized studies have examined the role of initial nephrectomy prior to interferon-alfa therapy in highly selected fit patients with metastases at diagnosis and minimal symptoms: despite minimal improvement in the chance of remission, both studies of up-front nephrectomy improved median survival by 4.8 months over interferon-alfa alone. Recent studies have been examining anti-angiogenesis agents. A landmark study of bevacizumab, an anti-vascular endothelial growth factor antibody, was associated with significant prolongation of the time to progression of disease when given at high dose compared to low-dose or placebo therapy though frequency of remissions or survival were not improved. AUTHORS' CONCLUSIONS: interferon-alfa provides a modest survival benefit compared to other commonly used treatments and should be considered for the control arm of future studies of systemic agents. In fit patients with metastases at diagnosis and minimal symptoms, nephrectomy followed by interferon-alfa gives the best survival strategy for fully validated therapies. The need for more effective specific therapy for this condition is apparent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Improving the Quality of Reporting of Randomized Controlled Trials: The CONSORT Statement
Begg, C. (1996) · JAMA · doi:10.1001/jama.1996.03540080059030 · Cited by 3,127
Rosenberg, S. A., Lotze, M. T., Muul, L. M., Chang, A. E., Avis, F. P., Leitman, S., Linehan, W. M., Robertson, C. N., Lee, R. E., Rubin, J. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198704093161501 · Cited by 2,735
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Flanigan, R. C., Salmon, S. E., Blumenstein, B. A., Bearman, S. I., Roy, V., McGrath, P. C., Caton, J. R., Munshi, N., & Crawford, E. D. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa003013 · Cited by 1,715
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,554
Mickisch, G., Garin, A., van Poppel, H., de Prijck, L., & Sylvester, R. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06103-7 · Cited by 1,410
Fyfe, G., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.3.688 · Cited by 1,391
Negrier, S., Escudier, B., Lasset, C., Douillard, J.-Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381805 · Cited by 967
Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S.-H., Marshall, B., Boni, J. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.185 · Cited by 942
McDermott, D. F., Regan, M. M., Clark, J. I., Flaherty, L. E., Weiss, G. R., Logan, T. F., Kirkwood, J. M., Gordon, M. S., Sosman, J. A., Ernstoff, M. S., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.206 · Cited by 820
Randomized Study of High-Dose and Low-Dose Interleukin-2 in Patients With Metastatic Renal Cancer
Yang, J. C., Sherry, R. M., Steinberg, S. M., Topalian, S. L., Schwartzentruber, D. J., Hwu, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., White, D. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.122 · Cited by 790
Survival Analysis: A Practical Approach.
Smith, P. J., Parmar, M. K. B., & David, M. (1996) · Journal of the American Statistical Association · doi:10.2307/2291609 · Cited by 730
Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.622 · Cited by 639
SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA
MOTZER, R. J., & RUSSO, P. (2000) · Journal of Urology · doi:10.1016/s0022-5347(05)67889-5 · Cited by 603
(1999) · The Lancet · doi:10.1016/s0140-6736(98)03544-2 · Cited by 601
The Genetic Basis of Cancer of the Kidney
LINEHAN, W. M., WALTHER, M. M., & ZBAR, B. (2003) · Journal of Urology · doi:10.1097/01.ju.0000096060.92397.ed · Cited by 470
Siegel, J. P., & Puri, R. K. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.4.694 · Cited by 465
Pyrhönen, S., Salminen, E., Ruutu, M., Lehtonen, T., Nurmi, M., Tammela, T., Juusela, H., Rintala, E., Hietanen, P., & Kellokumpu-Lehtinen, P.-L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2859 · Cited by 441
(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.2.671 · Cited by 431
Simons, J. W., Jaffee, E. M., Weber, C. E., Levitsky, H. J., Nelson, W. G., Carducci, M. A., Lazenby, A. J., Cohen, L. K., Finn, C. C., Clift, S. M., et al. (1998) · The Journal of Urology · doi:10.1097/00005392-199802001-00032 · Cited by 410
Rini, B. I., & Small, E. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.186 · Cited by 408
Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma
Gleave, M. E., Elhilali, M., Fradet, Y., Davis, I., Venner, P., Saad, F., Klotz, L. H., Moore, M. J., Paton, V., Bajamonde, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381804 · Cited by 308
Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma.
Quesada, J. R., Rios, A., Swanson, D., Trown, P., & Gutterman, J. U. (1985) · Journal of Clinical Oncology · doi:10.1200/jco.1985.3.11.1522 · Cited by 272
Motzer, R. J., Murphy, B. A., Bacik, J., Schwartz, L. H., Nanus, D. M., Mariani, T., Loehrer, P., Wilding, G., Fairclough, D. L., Cella, D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2972 · Cited by 264
(2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00637-8 · Cited by 232
Atzpodien, J., Kirchner, H., Jonas, U., Bergmann, L., Schott, H., Heynemann, H., Fornara, P., Loening, S. A., Roigas, J., Müller, S. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.155 · Cited by 223
Vogelzang, N. J., & Stadler, W. M. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01041-1 · Cited by 222
Figlin, R. A., Thompson, J. A., Bukowski, R. M., Vogelzang, N. J., Novick, A. C., Lange, P., Steinberg, G. D., & Belldegrun, A. S. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2521 · Cited by 212
Designing a Practice Policy: Standards, Guidelines, and Options
Eddy, D. M. (1990) · JAMA · doi:10.1001/jama.1990.03440220105041 · Cited by 207
Scott, O. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.250 · Cited by 186
Contemporary approach to the classification of renal epithelial tumors.
Reuter, V. E., & Presti, J. C. (2000) · PubMed · Cited by 182
Negrier, S., Perol, D., Menetrier-Caux, C., Escudier, B., Pallardy, M., Ravaud, A., Douillard, J.-Y., Chevreau, C., Lasset, C., & Blay, J.-Y. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.121 · Cited by 176
Yang, J. C., Topalian, S. L., Parkinson, D., Schwartzentruber, D. J., Weber, J. S., Ettinghausen, S. E., White, D. E., Steinberg, S. M., Cole, D. J., & Kim, H. I. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.8.1572 · Cited by 170
Is there logic in the placebo?
Gøtzsche, P. C. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92273-x · Cited by 169
Thiesse, P., Ollivier, L., Di Stefano-Louineau, D., Négrier, S., Savary, J., Pignard, K., Lasset, C., & Escudier, B. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.12.3507 · Cited by 168
Fyfe, G. A., Fisher, R. I., Rosenberg, S. A., Sznol, M., Parkinson, D. R., & Louie, A. C. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2410 · Cited by 163
Figlin, R. A., Pierce, W. C., Kaboo, R., Tso, C. L., Moldawer, N., Gitlitz, B., deKernion, J., & Belldegrun, A. (1997) · Journal of Urology · doi:10.1016/s0022-5347(01)64304-0 · Cited by 160
Fair Conduct and Fair Reporting of Clinical Trials
Rennie, D. (1999) · JAMA · doi:10.1001/jama.282.18.1766 · Cited by 158
Cancer and Leukemia Group B 90206
Rini, B. I., Halabi, S., Taylor, J., Small, E. J., Schilsky, R. L., & for the Cancer Leukemia Group B (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0605 · Cited by 153
Curti, B. D. (2004) · JAMA · doi:10.1001/jama.292.1.97 · Cited by 150
Négrier, S., Caty, A., Lesimple, T., Douillard, J., Escudier, B. J., Rossi, J., Viens, P., & Gomez, F. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.24.4009 · Cited by 135
D. G. C. I. N. (German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group), Atzpodien, J., Kirchner, H. H., Illiger, H. J., Metzner, B., Ukena, D., Schott, H., Funke, P.-J., Gramatzki, M., von Jürgenson, S., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2076 · Cited by 133
Motzer, R. J., Rakhit, A. K., Thompson, J. A., Nemunaitis, J. J., Murphy, B. A., Ellerhorst, J. A., Schwartz, L. H., Berg, W. J., & Bukowski, R. M. (2001) · Journal of Interferon & Cytokine Research · doi:10.1089/107999001750169934 · Cited by 127
Neidhart, J. A., Anderson, S. A., Harris, J. E., Rinehart, J. J., László, J., Dexeus, F. H., Einhorn, L. H., Trump, D. L., Benedetto, P. W., & Tuttle, R. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.5.832 · Cited by 103
Aass, N., Mulder, P. H. M. D., Mickisch, G., Mulders, P., van Oosterom, A. T., van Poppel, H., Fosså, S. D., de Prijck, L., & Sylvester, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.114 · Cited by 98
Yang, J. C.-H., Topalian, S. L., Schwartzentruber, D. J., Parkinson, D. R., Marincola, F. M., Weber, J. S., Seipp, C. A., White, D. E., & Rosenberg, S. A. (1995) · Cancer · Cited by 94
Dutcher, J. P., Atkins, M. B., Fisher, R. I., Weiss, G. R., Margolin, K. A., Aronson, F. R., Sosman, J. A., Lotze, M. T., Gordon, M. S., Logan, T. F., et al. (1997) · PubMed · Cited by 67
Bois, J. S. D., Trehu, E., Mier, J. W., Shapiro, L., Epstein, M., Klempner, M. S., Dinarello, C. A., Kappler, K., Ronayne, L., Rand, W., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1052 · Cited by 58
Bacik, J., Mazumdar, M., Murphy, B. A., Fairclough, D. L., Eremenco, S., Mariani, T. V., Motzer, R. J., & Cella, D. F. (2004) · Quality of Life Research · doi:10.1023/b:qure.0000015297.91158.01 · Cited by 50
Adler, A. G., GILLON, G., Lurie, H., et al. (1987) · PubMed · Cited by 37
Royston, P. J., Sauerbrei, W., & Ritchie, A. W. S. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601622 · Cited by 32
Graham, S. D., Babayan, R. K., Dl, L., Sawczuk, I. S., Ross, S. D., Lavin, P. T., Osband, M. E., & Krane, R. J. (1993) · PubMed · Cited by 32
Donskov, F. N., Middleton, M. R., Fode, K., Meldgaard, P., Mansoor, W., Lawrance, J., Thatcher, N., Nellemann, H. M., & von der Maase, H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602768 · Cited by 28
Fosså, S. D., Mickisch, G., Mulder, P. H. M. D., Horenblas, S., van Oosterom, A. T., van Poppel, H., Fey, M. F., Croles, J. J., de Prijck, L., & Glabbeke, M. M. V. (2004) · Cancer · doi:10.1002/cncr.20307 · Cited by 27
Lissoni, P., agrave, M. M., & Brivio, F. (2000) · European Urology · doi:10.1159/000020263 · Cited by 27
Planned Equivalence or Noninferiority Trials Versus Unplanned Noninferiority Claims: Are They Equal?
Zee, B. C.-Y. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9684 · Cited by 23
Fayers, P. M., Cook, P., Machin, D., Donaldson, N., Whitehead, J., Ritchie, A. W. S., Oliver, R. T. D., & Yuen, P. (1994) · Statistics in Medicine · doi:10.1002/sim.4780132106 · Cited by 21
Immunotherapy of metastatic renal cell cancer
Goey, S. H., Verweij, J., & Stoter, G. (1996) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a010790 · Cited by 20
Ahmed, F. Y., Leonard, G., A’Hern, R., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.498 · Cited by 13
Immunotherapy: the last 25 years
Plunkett, T. A., & Miles, D. W. (1999) · Cancer Treatment Reviews · doi:10.1053/ctrv.1999.0135 · Cited by 6
Coppin, C., & Porzsolt, F. (2003) · Evidence-based Oncology · doi:10.1002/9780470987360.ch30 · Cited by 4
Self-citation
Cited by
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Ljungberg, B., Bensalah, K., Canfield, S., Dabestani, S., Hofmann, F., Hora, M., Kuczyk, M. A., Lam, T., Marconi, L., Merseburger, A. S., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.01.005 · Cited by 3,394
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Escudier, B., Pluzanska, A., Koralewski, P., Ravaud, A., Bracarda, S., Szczylik, C., Chevreau, C., Filipek, M., Melichar, B., Bajetta, E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61904-7 · Cited by 2,217
Heng, D. Y. C., Xie, W., Regan, M. M., Warren, M. A., Golshayan, A. R., Sahi, C., Eigl, B. J., Ruether, J. D., Cheng, T., North, S., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4809 · Cited by 2,133
Metadata
- Authors
- Coppin, C., Porzsolt, F., Autenrieth, M., Kumpf, J., Coldman, A., & Wilt, T.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2004-07-19
- Issue
- 1
- Pages
- CD001425-CD001425
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W1666874820
- Cited by
- 589
- References
- 66
- Type
- reference entry
- Language
- en
- Status
- Retracted
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.